Teriparatide nel trattamento dell’osteoporosi primaria e indotta da glucocorticoidi (GIO) in pazienti con Lupus Eritematoso Sistemico(LES): effetti sui marcatori del turnover osseo, e sui livelli sierici di osteoprotegerina(OPG), sRANKL, Interleuchina 6(IL -6) e Fattore di Necrosi Tumorale α (TNF-α )

We studied the effect of treatment with teriparatide,a bone forming agent,on a group of 30 patients with postmenopausal osteoporosis and 20 patients with Systemic Lupus Erythematosus and GIO.Twenty postmenopausal women with osteopososis served as a control group and ere treated with oral alendronate.Markers of bone turnover(BAP,ICTP and Ost),serum levels of osteoprotegerin and sRANKL,IL-6 and TNF α were measured under control conditions and after 12 and 18 months of therapy. Teriparatide administration was able to significantly increase BMD at lumbar and femoral levels in all of the treated patients.A 2-year course of treatment with alendronate increased BMD only at lumbar level. Measurement of bone turnover markers showed a strong bone stimulating action of teriparatide and only a antiresorptive effect of alendronate. Serum levels of IL-6 and TNFα were significantly reduced in all of the patients treated with teriparatide.